<div id="readability-page-1"><p>Nikko Asset Management Americas Inc. raised its position in shares of  Illumina, Inc. (NASDAQ:ILMN - Free Report) by 28.8% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor  owned 867,981 shares of the life sciences company's stock after purchasing an additional 194,243 shares during the quarter. Nikko Asset Management Americas Inc. owned 0.56% of Illumina worth $82,814,000 at the end of the most recent quarter.</p><ul><li>GRAIL: Biotech Stock Targeting $100B Cancer Market</li></ul><p>Several other hedge funds and other institutional investors have also recently made changes to their positions in ILMN. Charles Schwab Investment Management Inc. raised its holdings in  Illumina by 5.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 721,047 shares of the life sciences company's stock worth $57,208,000 after acquiring an additional 37,502 shares during the last quarter.  National Bank of Canada FI increased its holdings in shares of  Illumina by 75.7% in the 1st quarter. National Bank of Canada FI now owns 3,484 shares of the life sciences company's stock worth $276,000 after purchasing an additional 1,501 shares in the last quarter.  Invesco Ltd. raised its stake in shares of  Illumina by 61.2% in the first quarter. Invesco Ltd. now owns 908,534 shares of the life sciences company's stock worth $72,083,000 after purchasing an additional 344,795 shares during the last quarter.  Nuveen LLC purchased a new position in shares of  Illumina in the first quarter worth $23,744,000.  Finally, Resona Asset Management Co. Ltd. lifted its holdings in shares of  Illumina by 4.9% during the first quarter. Resona Asset Management Co. Ltd. now owns 47,542 shares of the life sciences company's stock valued at $3,776,000 after purchasing an additional 2,226 shares in the last quarter. Institutional investors own  89.42% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several equities research analysts recently commented on ILMN shares. Barclays lifted their price objective on Illumina from $95.00 to $100.00 and gave the stock an &#34;underweight&#34; rating in a report on Friday, October 31st. Weiss Ratings  reiterated a &#34;hold (c-)&#34; rating on shares of Illumina in a research note on Wednesday. TD Cowen increased their price objective on shares of Illumina from $110.00 to $115.00 and gave the company a &#34;hold&#34; rating in a research report on Friday, October 31st. Cowen  restated a &#34;hold&#34; rating on shares of Illumina in a report on Friday, October 31st. Finally, Canaccord Genuity Group boosted their target price on shares of Illumina from $105.00 to $112.00 and gave the company a &#34;hold&#34; rating in a research note on Friday, October 31st. One investment analyst  has rated the stock with a Strong Buy rating, five have issued  a Buy rating, thirteen have assigned  a Hold rating and two have assigned  a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and an average price target of $115.00.</p><ul><li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li></ul><p><b>Get Our Latest Report on ILMN</b></p><h2>Insider Activity at Illumina</h2><p>In related news, Director Scott Gottlieb acquired 500 shares of the stock in a transaction dated Monday, November 3rd. The shares were purchased at an average cost of $122.13 per share, with a total value of $61,065.00. Following the transaction, the director directly owned 12,523 shares in the company, valued at approximately $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.60% of the stock is owned by company insiders. </p><h2>Illumina Trading Down 1.2%</h2><ul><li>Palantir Was Left Out of the S&amp;P 500; It Still Looks Like a Buy</li></ul><p>Shares of Illumina stock opened at $134.87 on Friday. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $153.06. The company's fifty day simple moving average is $114.71 and its 200-day simple moving average is $102.75. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The stock has a market capitalization of $20.61 billion, a PE ratio of 30.24, a P/E/G ratio of 2.41 and a beta of 1.44. </p><p>Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the business posted $1.14 EPS. Illumina's revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS.  As a group, equities analysts anticipate that  Illumina, Inc. will post 4.51 earnings per share for the current year. </p><h2>Illumina Profile</h2> (Free Report)<p>Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Illumina</li><li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li><li>3 Defense Stocks Set to Benefit From Increased Military Spending</li><li>Why Amazon Could Be a $300 Stock Within Weeks</li><li>What Is WallStreetBets and What Stocks Are They Targeting?</li><li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUxNTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUxNTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Illumina Right Now?</h2><p>Before you consider Illumina, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.</p><p>While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ILMN

<p>Nikko Asset Management Americas Inc. increased its stake in Illumina, Inc. by 28.8% in Q2, owning 867,981 shares valued at $82.8 million. Other institutional investors also adjusted their positions in Illumina. Analysts have mixed ratings on the stock, with an average "Hold" rating and a target price of $115. Illumina's recent earnings exceeded expectations, with a reported EPS of $1.34 and revenue of $1.08 billion.</p>

Nikko Asset Management Americas Inc. Increases Stake in Illumina, Inc. $ILMN